This Rogue Doctor Wants to Charge Women $100,000 For an Illegal Fertility Treatment
By Kristen V. Brown,
Gizmodo
| 06. 16. 2017
Last fall, John Zhang made headlines after his fertility clinic announced that for the first time a baby had been born using a new technique requiring three genetic parents. The baby’s mother carried the genes for a fatal nervous system disorder called Leigh syndrome, but Zhang had been able to keep the disease from being inherited by her son by swapping in a donor’s mitochondrial DNA, the teeny bit of DNA where Leigh syndrome is housed. Since the technique is illegal in the US, the baby had been born in Mexico, where, as Zhang explained in a comment he might live to regret, “there are no rules.”
Now Zhang is taking his so-called “three-parent baby” technique commercial, and targeting a different market altogether: the booming, multi-billion dollar fertility market. Instead of focusing on women who risk passing on mitochondrial diseases to their offspring, he hopes to use the technique as a cure for infertility.
As the website for the company, Darwin Life, puts it: it’s a “revolutionary technology designed to reverse the effects of age on human oocytes...
Related Articles
By Tomoko Otake, The Japan Times | 04.09.2024
A decade ago, researcher Haruko Obokata caused a sensation when she published two papers in the journal Nature, in which she claimed that she had discovered a way to create stem cells easily using the so-called STAP method.
With STAP...
By Yelena Biberman and Jonathan D. Moreno, Bioethics Forum | 04.16.2024
A quiet biological revolution in warfare is underway. The genome is emerging as a new domain of conflict. The level of destruction that only nuclear weapons could previously achieve is fast becoming as accessible as a cyberattack.
Now for the...
CGS is excited to announce the launch of a new anti-eugenics initiative that has been years in the making. Legacies of Eugenics in Science, Medicine, and Technology kicks off with a monthly essay series published at the Los Angeles Review of Books that will expose and contest the reemergence of eugenic ideas in contemporary health sciences, human biotechnology, public health, and medicine. Community and campus-based events featuring the authors are also being planned. The project is a collaboration among CGS...
By Tristan Manalac, BioSpace | 04.02.2024
Verve Therapeutics has suspended enrollment in the Phase Ib Heart-1 study evaluating its lead gene editing program VERVE-101 following a serious adverse event, the company announced Tuesday.
A patient, who received a 0.45-mg/kg dose of VERVE-101, developed a grade 3...